Month: March 2026

Release NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer’s Readout

Posted on by aweinsoff@channelchek.com

Research News and Market Data on NRSN

CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today provided an update on key regulatory and clinical milestones for its lead asset, PrimeC.

Continue Reading

Health Canada Pre-NDS Meeting

A pre-New Drug Submission (pre-NDS) meeting with Health Canada has been rescheduled to May 2026.

The decision was made to allow for the inclusion of additional emerging clinical, biomarker and survival data and analyses in the briefing package, which the Company believes will meaningfully strengthen the scientific and clinical foundation supporting PrimeC.

The Company remains focused on advancing PrimeC under the NOC/c pathway in Canada, which is designed to facilitate earlier access to promising therapies addressing serious unmet medical needs.

Alzheimer’s Disease Program Update

The Company expects to report clinical and biomarker results from its Alzheimer’s study in the coming weeks.

Continued Momentum Across Key Programs

NeuroSense continues to advance its clinical and regulatory strategy for PrimeC, supported by our previously disclosed:

  • Statistically significant survival benefit (65% reduction in risk of death)
  • Expanding biomarker dataset supporting multi-mechanistic activity
  • FDA clearance to initiate the pivotal Phase 3 PARAGON trial in ALS

“As we generated additional valuable data, we believe it is strategic to incorporate these findings and analyses into our regulatory interactions,” said Alon Ben-Noon, Chief Executive Officer of NeuroSense. “Our objective is to present the most comprehensive and robust dataset possible to Health Canada, thereby maximizing the likelihood of a constructive and efficient regulatory pathway. We believe this approach positions the Company ahead of several important value inflection points across its ALS and Alzheimer’s programs expected in 2026.”

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

About PrimeC

PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (“RNA”) regulation to potentially inhibit the progression of ALS and AD.

About ALS

Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of regulatory filings, reporting of data, meetings and regulatory decisions. Further, certain forward-looking statements, including statements regarding future development of PrimeC, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding the timing of regulatory filings, meetings and regulatory decisions; outcomes and the timing of current and future clinical trials; the risk the PrimeC will not advance towards later-stage development, timing for reporting data, including from the study of PrimeC in Alzheimer’s disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 7, 2025 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

SOURCE NeuroSense

For further information: For further information: info@neurosense-tx.com, +972 (0)9 799 6183

Release – Bit Digital, Inc. Announces Date for Fourth Quarter and Fiscal Year 2025 Financial Results and Conference Call

Posted on by aweinsoff@channelchek.com

Research News and Market Data on BTBT

NEW YORK, March 24, 2026 /PRNewswire/ — Bit Digital, Inc. (Nasdaq: BTBT) (“Bit Digital” or the “Company”) today announced that it will release its financial results for the fourth quarter and fiscal year 2025, after the market closes on Tuesday, March 31, 2026.

Senior management will host a live webcast and conference call to discuss the results at 10:00 a.m. Eastern Time on Wednesday, April 1, 2026.

To register for the webcast, please click here. Participants may also join the conference call by dialing 1-800-330-6730 (passcode: 832471).

The earnings press release will be available on the Company’s website at www.bit-digital.com prior to the start of the call.

About Bit Digital
Bit Digital (NASDAQ: BTBT) is a Strategic Asset Company (SAC) focused on active participation in Ethereum infrastructure and controlling equity exposure to AI/HPC infrastructure through its majority ownership stake in WhiteFiber (NASDAQ: WYFI). The Company purchases and stakes ETH to generate protocol-native yield and participates directly in the Ethereum network. Bit Digital allocates capital with a focus on long-duration, foundational infrastructure, and disciplined balance sheet management. For additional information, please contact ir@bit-digital.com, visit our website at www.bit-digital.com or follow us on LinkedIn or X.

Investor Notice
Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks, uncertainties and forward-looking statements described under “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024 (Annual Report) and any subsequently filed Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K.  If any material risk was to occur, our business, financial condition or results of operations would likely suffer. In that event, the value of our securities could decline and you could lose part or all of your investment. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. In addition, our past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results in the future. See “Safe Harbor Statement” below.

Safe Harbor Statement
This press release may contain certain “forward-looking statements” relating to the business of Bit Digital, Inc., and its subsidiary companies. All statements, other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects,” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website at http://www.sec.gov. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Release – Bitcoin Depot Announces Executive Chair & CEO Transition; Names Alex Holmes as Chairman & CEO

Posted on by aweinsoff@channelchek.com

Research News and Market Data on BTM

March 24, 2026 8:00 AM EDT Download as PDF

Board Unanimously Appoints Veteran Fintech Executive with Deep Expertise in Global Payments, Digital Assets, and Regulatory Compliance

ATLANTA, March 24, 2026 (GLOBE NEWSWIRE) — Bitcoin Depot (NASDAQ: BTM) (“Bitcoin Depot” or the “Company”), a U.S.-based Bitcoin ATM operator and fintech company, today announced that Scott Buchanan has decided to step down as Chief Executive Officer, effective immediately, to pursue a new opportunity outside of the Company. The board of directors thank Scott for his many contributions and wish him well in his next chapter.

Effective immediately, Alex Holmes has been appointed Chief Executive Officer and Chairman of the Board. Holmes brings decades of executive leadership in global payments and fintech, most recently serving as Chairman and CEO of MoneyGram International, where he led the company’s transformation into a modern global fintech operating across more than 200 countries. The board is confident in his ability to lead Bitcoin Depot through its next phase of growth.

This transition comes as Bitcoin Depot continues to expand beyond its core BTM network into a broader suite of fintech and digital asset products, following recent strategic initiatives to diversify its platform and revenue streams.

Concurrently, Bitcoin Depot founder Brandon Mintz will transition from Executive Chair to a non-executive member of the board and is expected to serve as an advisor to the CEO. Mintz will work directly alongside Holmes, providing strategic continuity and institutional knowledge as the company executes its next phase. As the founder who built Bitcoin Depot into one of the largest Bitcoin ATM networks in the United States, Mintz remains a long-term shareholder.

Over a sixteen-year tenure at MoneyGram International, Holmes held executive roles as CFO and COO before serving as Chairman and CEO from 2016 to 2024, where he led the company’s transformation, earning a reputation for operational excellence, rigorous risk management, and global regulatory compliance expertise. Holmes most recently served as Executive Vice Chairman of United Texas Bank, a leader in correspondent banking and U.S. dollar clearing for crypto-focused institutions, where he also serves on the Board Risk Committee.

“During my time on Bitcoin Depot’s board of directors, I’ve developed a deep understanding and appreciation for our business, our customers, and our positioning in the market,” said Alex Holmes, Chairman and CEO of Bitcoin Depot. “As I step into the role, my priorities are operational stability, regulatory progress, and accelerating the Company’s evolution into a more diversified fintech platform. I look forward to working closely with the team and keeping stakeholders informed as we execute against these priorities.”

Bradley Strock, lead independent director of Bitcoin Depot, commented: “Alex has been a trusted voice on our board. We are excited to have someone of his caliber and experience step in to lead the company at this important juncture. His experience navigating complex, highly regulated global businesses, combined with his firsthand track record integrating blockchain technology into mainstream financial services and his deep public market experience, makes him the right person to lead Bitcoin Depot as it scales beyond its BTM foundation into a broader, more diversified fintech platform.”

Mintz commented: “Bitcoin Depot is my life’s work, and I remain deeply invested in its success as a shareholder, a director, and as an advisor to Alex and the leadership team. I have full confidence in this transition and in the path ahead for this company and the people who have built it.”

About Bitcoin Depot 
Bitcoin Depot Inc. (Nasdaq: BTM) was founded in 2016 with the mission to connect those who prefer to use cash to the broader, digital financial system. Bitcoin Depot provides its users with simple, efficient and intuitive means of converting cash into Bitcoin, which users can deploy in the payments, spending and investing space. Users can convert cash to bitcoin at Bitcoin Depot kiosks in 47 states and at thousands of name-brand retail locations in 31 states through its BDCheckout product. The Company has the largest market share in North America and operates over 9,000 kiosk locations globally as of August 2025. Learn more at www.bitcoindepot.com.

Cautionary Note Regarding Forward-Looking Statements
This press release and any oral statements made in connection herewith include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. Forward-looking statements are any statements other than statements of historical fact, and include, but are not limited to, statements regarding the expectations of plans, business strategies, objectives and growth and anticipated financial and operational performance, including our growth strategy and ability to increase deployment of our products and services, the anticipated effects of the Agreement. These forward-looking statements are based on management’s current beliefs, based on currently available information, as to the outcome and timing of future events. Forward-looking statements are often identified by words such as “anticipate,” “appears,” “approximately,” “believe,” “continue,” “could,” “designed,” “effect,” “estimate,” “evaluate,” “expect,” “forecast,” “goal,” “initiative,” “intend,” “may,” “objective,” “outlook,” “plan,” “potential,” “priorities,” “project,” “pursue,” “seek,” “should,” “target,” “when,” “will,” “would,” or the negative of any of those words or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. In making these statements, we rely upon assumptions and analysis based on our experience and perception of historical trends, current conditions, and expected future developments, as well as other factors we consider appropriate under the circumstances. We believe these judgments are reasonable, but these statements are not guarantees of any future events or financial results. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control.

These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; failure to realize the anticipated benefits of the business combination; future global, regional or local economic and market conditions; the development, effects and enforcement of laws and regulations; our ability to manage future growth; our ability to develop new products and services, bring them to market in a timely manner and make enhancements to our platform; the effects of competition on our future business; our ability to issue equity or equity-linked securities; the outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries; and those factors described or referenced in filings with the Securities and Exchange Commission. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that we do not presently know or that we currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect our expectations, plans or forecasts of future events and views as of the date of this press release. We anticipate that subsequent events and developments will cause our assessments to change.

We caution readers not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update publicly or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other factors that affect the subject of these statements, except where we are expressly required to do so by law. All written and oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary statement.

Contacts:
Investors & Media
Gateway Group, Inc. 
949-574-3860 
BTM@gateway-grp.com

Primary Logo

Source: Bitcoin Depot Inc.

Released March 24, 2026

Release – Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Posted on by aweinsoff@channelchek.com

Research News and Market data on OCGN

March 24, 2026

PDF Version

  • Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05)
  • Potential 2X treatment benefit compared to 15% and 22% reductions reported for currently approved therapies at 12 and 24 months, respectively
  • No serious adverse events and no adverse events of special interest related to OCU410 reported to date

MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced positive 12-month data from the Phase 2 ArMaDa clinical trial evaluating OCU410 (AAV5-RORA), its novel modifier gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD). The global prevalence of dAMD is 266 million worldwide, and GA affects approximately 2-3 million people in the United States (U.S.) and Europe. Importantly, this number is expected to increase significantly as populations age.

There are limited options for patients with dAMD in the U.S. and current therapies require 6–12 injections per year indefinitely, leading to substantial burden and significant dropout rates in real-world practice. Outside of the U.S., there are no approved products available.

Key findings from Phase 2 include:

  • 31% reduction in lesion growth in the optimal dose (medium) group compared to control (p< 0.05)
  • 27% slower rate of ellipsoid zone (EZ) loss compared to control, indicating structural preservation of photoreceptors, which correlates with visual function
  • 55% of treated patients demonstrated ≥30% lesion size reduction vs. control
  • Subgroup analysis (subjects with baseline GA lesions ≥5 mm2 and ≤17.5 mm2) showed 33% reduction in lesion growth compared to control in medium dose OCU410 with similar reductions in the high dose group

The Phase 2 clinical trial builds directly on the clean safety profile observed in Phase 1 with no OCU410-related serious adverse events observed and no cases of endophthalmitis, retinal detachment, vasculitis, choroidal neovascularization, or ischemic optic neuropathy reported to date.

GA is a multifactorial disease with a complex etiology that involves genetic and environmental factors. The current treatment options for GA in the U.S. are limited to those targeting a single mechanism—the complement pathway. By contrast, OCU410 is a first-in-class RORA-based gene therapy designed to support central retina and photoreceptor integrity through a multi-pathway mechanism—targeting drusen, inflammation, oxidative stress, and complement activation.​

“We have confirmed robust treatment effect from a well-controlled Phase 2 trial of a genetic medicine for GA. Now we can move on to Phase 3 with a high degree of confidence,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “This moves us one step closer to bringing a transformative one-time treatment to GA patients globally who are desperately seeking rescue from vision loss.”

“Our Phase 2 data consistently demonstrates statistically significant reduction of GA lesion growth after treatment with OCU410 optimal dose, and we continue to benchmark these results against natural history data to contextualize the magnitude of effect,” said Huma Qamar, MD, MPH, CMI, Chief Medical Officer of Ocugen. “We are incorporating these learnings into an anticipated Phase 3 pivotal confirmatory trial with up to 300 subjects and an adaptive design powered at over 95%.​”

“There remains a considerable unmet need in treating patients with GA and I am encouraged by the various analyses of the Phase 2 OCU410 data,” said Lejla Vajzovic, MD, FASRS, Director, Duke Surgical Vitreoretinal Fellowship Program, Associate Professor of Ophthalmology with Tenure, Adult and Pediatric Vitreoretinal Surgery and Disease, Duke University Eye Center, and Chair, Ocugen Retina Scientific Advisory Board. “In addition to the strong efficacy and safety data, OCU410 has the potential to eliminate the chronic treatment burden associated with monthly or every-other-month intravitreal injections and to reduce treatment attrition driven by patient fatigue.​”

In the Phase 2 study, the safety and efficacy of OCU410 in patients with GA secondary to dAMD are being assessed. Fifty-one (51) patients aged 50 years and older with GA lesions within the foveal or non-foveal region were randomized 1:1:1 to receive a single subretinal administration of OCU410 at a medium dose of 1 × 1010 vector genomes per eye, a high dose of 3 × 1010 vector genomes per eye, or no treatment in the control group; each injection volume was 200 microliters. Of note, choroidal neovascularization in the fellow eye was not exclusionary, and patients with prior exposure to pegcetacoplan or avacincaptad pegol were eligible following a three-month washout.

The primary endpoint was change in GA lesion size at 12 months, measured in square millimeters by fundus autofluorescence, an FDA-accepted structural endpoint used in recent GA registration trials. Exploratory endpoints included EZ preservation on OCT a key biomarker for photoreceptor integrity, which correlates with visual function.

Ocugen plans to initiate the OCU410 Phase 3 registrational trial in the third quarter of 2026 in line with the Company’s goal of three BLA filings in three years.

About dAMD and Geographic Atrophy
Geographic atrophy is an advanced form of dAMD characterized by progressive degeneration of the macula, leading to irreversible central vision loss. Millions of patients worldwide are affected by GA, with a particularly high burden in aging populations in the United States and Europe. Despite recent approvals, treatment options remain limited and require chronic intravitreal injections, underscoring the need for innovative, durable therapies that address multiple disease mechanisms. dAMD affects approximately 10 million Americans and more than 266 million people worldwide. It is characterized by the thinning of the macula, the portion of the retina responsible for clear vision in one’s direct line of sight. dAMD involves the slow deterioration of the retina with submacular drusen (small white or yellow dots on the retina), atrophy, loss of macular function, and central vision impairment. dAMD accounts for 85-90% of all AMD cases.

About OCU410
OCU410 is an investigational, subretinal injection, AAV5-based gene therapy that delivers RORA (retinoid-related orphan receptor alpha), a nuclear receptor that regulates key pathways involved in retinal homeostasis, including oxidative stress response, complement regulation, inflammation, and lipid metabolism. OCU410 is being developed as a one-time gene therapy for patients with GA secondary to dry AMD. OCU410 has received Advanced Therapy Medicinal Product (ATMP) classification from the European Medicines Agency.

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies to address major blindness diseases and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; the ability of OCU410 to perform in humans in a manner consistent with nonclinical, preclinical or previous clinical study data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com

Release – Perfect’s Board Announces the Formation of Special Committee to Evaluate on the Preliminary Non-Binding “Going Private” Proposal Received on March 18, 2026

Posted on by aweinsoff@channelchek.com

Research News and Market Data on PERF

March 23, 2026

NEW YORK–(BUSINESS WIRE)– Perfect Corp. (NYSE: PERF) (“Perfect” or the “Company”), a leading artificial intelligence (“AI”) company offering AI and augmented reality (“AR”) powered solutions to beauty, fashion, photo and video creative industries, today announced that its board of directors (the “Board”) has formed a special committee (the “Special Committee”) consisting of three disinterested, independent directors, namely Philip Tsao, who will serve as the chairman of the Special Committee, Chung-Hui (Christine) Jih and Meng-Shiou (Frank) Lee, to evaluate and consider the preliminary non-binding proposal letter, received on March 18, 2026 (the “Proposal”) from the consortium formed by CyberLink International Technology Corp. (“CyberLink”) and Ms. Alice H. Chang, Chairwoman of the Board and Chief Executive Officer of Perfect and her controlled entities, that proposes a “going-private” transaction for US$1.95 per ordinary share in cash (the “Transaction”).

The Special Committee is authorized to retain advisors, including independent legal and financial advisors, to assist it in its work.

The Company cautions its shareholders and others considering trading in its securities that neither the Board nor the Special Committee has made any decision with respect to the Company’s response to the Proposal. There can be no assurance that any definitive offer will be received, that any definitive agreement will be executed relating to the Transaction, or that the Transaction or any other similar transaction will be approved or consummated. The Company does not undertake any obligation to provide any updates with respect to any transaction, except as required under applicable law.

About Perfect Corp.

Founded in 2015, Perfect Corp. is a leading AI company offering self-developed AI- and AR-powered solutions dedicated to transforming the world with digital tech innovations that make your virtual world beautiful. On Perfect’s direct consumer business side, Perfect operates a family of YouCam consumer apps and web-editing services for photo, video and camera users, centered on unleashing creativity with AI-driven features for creation, beautification and enhancement. On Perfect’s enterprise business side, Perfect empowers major beauty, skincare, fashion, jewelry, and watch brands and retailers by supplying them with omnichannel shopping experiences through AR product try-ons and AI-powered skin diagnostics. With cutting-edge technologies such as Generative AI, real-time facial and hand 3D AR rendering and cloud solutions, Perfect enables a personalized, enjoyable, and engaging shopping journey and helps brands elevate customer engagement, increase conversion rates, and propel sales growth. Throughout this journey, Perfect maintains its unwavering commitment to environmental sustainability and fulfilling social responsibilities. For more information, visit https://ir.perfectcorp.com/.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, that are based on beliefs and assumptions and on information currently available to Perfect. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including strategies or plans, are also forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These statements are based on Perfect’s reasonable expectations and beliefs concerning future events and involve risks and uncertainties that may cause actual results to differ materially from current expectations. These factors are difficult to predict accurately and may be beyond Perfect’s control. Forward-looking statements in this communication or elsewhere speak only as of the date made. New uncertainties and risks arise from time to time, and it is impossible for Perfect to predict these events or how they may affect Perfect. In addition, risks and uncertainties are described in Perfect’s filings with the Securities and Exchange Commission. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Perfect cannot assure you that the forward-looking statements in this communication will prove to be accurate. There may be additional risks that Perfect presently does not know or that Perfect currently does not believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by Perfect, its directors, officers or employees or any other person that Perfect will achieve its objectives and plans in any specified time frame, or at all. Except as required by applicable law, Perfect does not have any duty to, and does not intend to, update or revise the forward-looking statements in this communication or elsewhere after the date of this communication. You should, therefore, not rely on these forward-looking statements as representing the views of Perfect as of any date subsequent to the date of this communication.

Investor Relations Contact
Investor Relations, Perfect Corp.
Email: Investor_Relations@PerfectCorp.com

Source: Perfect Corp.

Banzai’s Bold Bet: Microcap MarTech Player Eyes Revenue-Doubling Acquisition of ConnectAndSell

Posted on by slightbourne@noblecapitalmarkets.com

Banzai International (Nasdaq: BNZI) just made a move that could fundamentally reshape what the microcap marketing technology company looks like by summer — and the numbers tell a striking story.

The Austin-based AI marketing platform announced late last week that it has reached terms to acquire the assets of ConnectAndSell, an AI-powered sales acceleration platform serving B2B organizations across healthcare, financial services, and technology. The deal, structured around a non-binding letter of intent, is expected to close in early Q2 2026, pending a definitive agreement and customary closing conditions.

The strategic rationale is straightforward on paper: Banzai recorded approximately $10.65 million in revenue over the trailing twelve months ending Q3 2025. The ConnectAndSell acquisition is projected to add roughly $15 million in annual revenue — meaning the deal alone would more than double the company’s current revenue run rate if integration goes according to plan. For a company with a market cap hovering around $14 million, that kind of top-line expansion isn’t incremental — it’s transformational.

ConnectAndSell is not a startup. It is an established, profitable business with a track record of generating real revenue across enterprise and mid-market accounts. Its platform is designed to dramatically increase sales team productivity by maximizing time spent in live conversations with qualified decision-makers — a capability that sits at the highest-value stage of the go-to-market funnel. For Banzai, which already helps companies target, engage, and measure marketing outcomes, layering in sales execution capabilities creates an end-to-end revenue platform that few companies at this market cap can claim.

The deal follows Banzai’s acquisition of Superblocks in November 2025, an agentic AI platform for SEO-optimized website development. The pattern is becoming clear: Banzai is pursuing a deliberate build-out strategy, acquiring profitable, AI-native tools that are immediately accretive and strategically complementary rather than chasing speculative moonshots.

Cross-sell opportunity is a core part of the investment thesis here. Banzai’s existing customer base includes more than 140,000 organizations — among them RBC, Dell Technologies, New York Life, and Thermo Fisher Scientific. Introducing ConnectAndSell’s sales acceleration capability to even a fraction of that base could generate meaningful incremental revenue beyond the $15 million headline figure.

Still, investors should keep a few realities in check. The transaction remains at the letter of intent stage — no definitive agreement has been signed, and no purchase price has been disclosed, creating near-term financial transparency uncertainty. Banzai’s stock has also declined roughly 89% over the past year, sitting just below the $1 mark, which reflects a company that has been fighting uphill on the balance sheet even as it executes strategically. Management is scheduled to discuss the proposed acquisition in detail on a conference call March 31, 2026 at 4:30 p.m. Eastern Time, which will be the next critical data point for investors watching this deal develop.

For small and microcap investors, Banzai’s acquisition playbook is worth watching. In a market where platform consolidation is increasingly the path to survival and scale, companies that can string together profitable, AI-powered assets at reasonable valuations may be positioning themselves for an outsized rerating when the market conditions turn. Whether BNZI can execute on that vision is the question the rest of 2026 will answer.

GDEV (GDEV) – Improved Profitability Appears Sustainable

Posted on by slightbourne@noblecapitalmarkets.com


Tuesday, March 24, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Solid Q4 results. The company reported Q4 revenue of $90.0 million and adj. EBITDA of $15.0 million. While revenue was modestly below our estimate of $99.0 million, adj. EBITDA was in line with our estimate of $15.1 million. Notably, the strong adj. EBITDA figure was largely driven by more efficient use of marketing spend, which decreased approximately 25% compared to the prior year period.

Key operating metrics. Bookings and monthly paying users (MPU) decreased by 7% and 10%, respectively, compared with the prior year period, but the decrease was expected as the company is focused on the quality of gameplay and retaining high-quality users. Furthermore, the company’s strategy appears to be paying off, as average bookings per paying user (ABPPU) increased from $102 in Q4’24 to $106 in Q4’25.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Trump Pays a French Energy Giant to Exit U.S. Offshore Wind — and Redirects the Money to Fossil Fuels

Posted on by slightbourne@noblecapitalmarkets.com

The Trump administration has agreed to refund $1 billion in offshore wind lease fees to French energy giant TotalEnergies, effectively paying the company to abandon two major U.S. wind projects and redirect that capital into oil, gas, and liquefied natural gas development. The move marks one of the most aggressive — and costly — steps yet in the administration’s campaign to dismantle the offshore wind industry built up under the Biden era.

The Department of Interior announced Monday that TotalEnergies will surrender its leases for planned offshore wind projects off the coasts of North Carolina and New York. In exchange, the company will receive reimbursement up to the full amount it paid to acquire those leases. TotalEnergies has also pledged not to pursue any new offshore wind development in the United States. The refunded capital will be redirected toward the construction of a liquefied natural gas facility in Texas and the expansion of the company’s broader U.S. oil and gas portfolio.

For context, TotalEnergies paid roughly $133,000 for the North Carolina lease and approximately $795,000 for the New York and New Jersey lease — both purchased in 2022 during the height of the Biden administration’s offshore wind push. The Carolina Long Bay project had been designed to generate over one gigawatt of power, enough to supply roughly 300,000 homes. The New York project was even larger, with a planned capacity of three gigawatts capable of powering close to one million homes.

The deal raises immediate questions about the use of public funds. Environmental advocates were quick to characterize it as taxpayer money being spent to eliminate clean energy capacity rather than build it — particularly at a moment when the Iran conflict has sent oil prices surging and renewed global debate about energy security and diversification.

This transaction also comes after the administration’s earlier attempts to halt offshore wind construction were struck down by federal courts. Judges overturned executive orders that had targeted five major East Coast wind projects on national security grounds, allowing construction to continue. The TotalEnergies deal appears to signal a strategic pivot — using financial settlements to achieve what legal orders could not.

The broader energy policy picture is shifting rapidly. Ironically, on the same day this deal was announced, one of the offshore wind farms previously targeted by the administration — Coastal Virginia Offshore Wind — began delivering power to the Virginia grid. The developer, Dominion Energy, confirmed the milestone, underscoring the fact that the offshore wind industry, despite significant political headwinds, continues to advance.

For investors in the small and microcap energy space, the implications cut both ways. Companies with exposure to LNG infrastructure, domestic oil and gas development, and fossil fuel supply chains stand to benefit from the administration’s policy direction and capital reallocation. On the other side, smaller renewable energy developers and wind supply chain companies face an increasingly hostile regulatory and financial environment in the U.S., even as offshore wind capacity expands globally — with China leading the world in new installations.

The $1 billion question is whether this deal represents a one-time settlement or the beginning of a broader pattern of government-funded exits from the U.S. renewable energy sector.

Release – Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026

Posted on by aweinsoff@channelchek.com

Research News and Market Data on TNXP

March 23, 2026 4:32pm EDTDownload as PDF

Monday, March 30: Phase 1 data on TNX-4800 (long-acting anti-Borrelia OspA human monoclonal antibody) for the seasonal prevention of Lyme disease 

Wednesday, April 1: Animal and in vitro studies on TNX-801 (horsepox, live virus vaccine) for the prevention of smallpox and mpox

Wednesday, April 1: Horsepox as a modular antigen-delivery system for broad and sustained immunity in novel vaccines to protect against other pathogens

BERKELEY HEIGHTS, N.J., March 23, 2026 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, today announced an oral presentation of Phase 1 data on TNX-4800 (formerly known as mAb 2217LS)1,2, a long-acting human monoclonal antibody (mAb) that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the causative agent of Lyme disease in humans in the U.S., at the World Vaccine Congress Washington 2026 held in Washington, D.C., March 30-April 2, 2026.

The Company’s Farooq Nasar, PhD, Director, Virology will present data on TNX-801, the Company’s attenuated, live orthopoxvirus (horsepox) vaccine candidate with the potential capability to protect against smallpox and mpox. Finally, Christopher Cooper, PhD, Director, Immunology at Tonix will serve as moderator on a panel discussing modular antigen-delivery systems in novel pox-based vaccines.

TNX-4800 Presentation Details

Title: A Long-Acting Monoclonal Antibody for Seasonal Prevention of Lyme Disease
Location: Room 202B
Date and Time: March 30, 2026, 10:10 a.m. ET
Session Category: Measuring Breadth & Emerging Targets
Presenters: Mark S. Klempner, MD, Professor of Medicine at UMass Chan Medical School, inventor of TNX-4800, and Principal Investigator of the study

Other Session Details

Title: A Live Attenuated, Minimally Replicative MPOX Vaccine
Location: Room 202A, Level 2
Date and Time: April 1, 2026, 10:10 am ET
Session Category: Emerging & Re-Emerging Diseases
Presenter: Farooq Nasar, PhD, Director, Virology, Research and Development Center (RDC), Tonix Pharmaceuticals

Title: Poxvirus as a Modular Antigen-Delivery System for Broad and Sustained Immunity
Location: Room 20A, Level 2
Date and Time: April 1, 2026, 3:25 p.m. ET
Session Category: Emerging & Re-Emerging Diseases
Moderator: Christopher Cooper, PhD, Director, Immunology, RDC, Tonix Pharmaceuticals

About TNX-4800
TNX-4800 (formerly known as mAb 2217LS) is a human monoclonal antibody with an engineered extended half-life that targets the outer-surface protein A (OspA) on Lyme-causing Borrelia bacteria. When TNX-4800-containing blood is ingested by the tick, TNX-4800 kills and blocks the maturation of Borrelia burgdorferi in the mid-gut of infected deer ticks. The Company in-licensed TNX-4800 from UMass Chan Medical School in 2025. Published work in animals showed that TNX-4800 was 95% effective in preventing infection after a six-day challenge with ticks infected with Borrelia burgdorferi.1 TNX-4800 was derived from mAb 2217 by amino acid substitutions in its crystallizable fragment (Fc) domain which serve to prolong the serum half-life. A single administration in the Spring is designed to potentially provide immunity within two days and maintain protective antibody titers for the entire tick season, providing pre-exposure prophylaxis against Lyme disease without relying on the recipient’s immune system to generate antibodies. By delivering a well-characterized antibody directly, TNX-4800 has been shown to block transmission of Borrelia burgdorferi from ticks to animals. TNX-4800 also sidesteps the multidose schedules required for OspA vaccines in development3 and the FDA-approved vaccine that was withdrawn from the market.4 The Company expects to have GMP investigational product available for clinical testing in early 2027. Pending FDA clearances, a field study is expected to initiate enrollment in the first half of 2027, and a controlled human infection model (CHIM) study in 2028.

About the TNX-4800 Phase 1 Study
TNX-4800 was studied in a randomized, double-blind, sequential dose-escalation study (NCT04863287) that evaluated safety, tolerability, pharmacokinetics (PK), and immunogenicity of TNX-4800 in healthy adults. 44 subjects were randomized, and 41 completed the study. Subjects received a single subcutaneous (SC) administration of placebo or TNX-4800 at 0.5, 1.5, 5, or 10 mg/kg. Safety was assessed via clinical and lab evaluations. Drug exposure increased by approximately 25 times for a 20 times increase in dose. Serum TNX-4800 was measurable at the earliest sampling time of 24 hours, indicating rapid systemic absorption. TNX-4800 concentrations remained quantifiable for >200 days in 80% of volunteers at the lowest dose and for up to 350 days in the majority of volunteers at higher doses (i.e., ≥ 1.5 mg/kg). Mean half-life ranged from 62-69 days across groups. Serum concentrations remained quantifiable for up to 12 months in most subjects. Mean exposure for the 10 mg/kg cohort was less than 20% of the highest exposures in a rat toxicology study. Anti-drug antibodies (ADA) were detected in <10% of treated subjects, with no impact on PK. Most adverse events were mild or moderate. TNX-4800 was determined to be generally safe and well tolerated.

About Lyme Disease 
In the United States, Lyme disease is caused by the bacterium Borrelia burgdorferi. Lyme disease remains the most common vector-borne infection in the United States, and its incidence is climbing each year, due in part to global changes in climate expanding the habitat range for ticks.5 It occurs most commonly in the Northeast, mid-Atlantic, and upper-Midwest regions. Lyme disease bacteria are transmitted through the bite of infected Ixodes ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans. If left untreated, infection can spread to joints, heart, and nervous system. Laboratory testing is helpful if used correctly and performed with FDA-cleared tests. Although many cases of Lyme disease can be treated successfully with antibiotics, diagnosis and treatment are often delayed or missed. Chronic Lyme is considered an Infection Associated Chronic Illness (IACI), and is a chronic, debilitating disease state characterized by joint and muscle pain, fatigue, and other symptoms.6

About TNX-801
TNX-801 (recombinant horsepox virus) is an attenuated, minimally replicative, live virus vaccine based on horsepox in pre-clinical development to prevent mpox and smallpox. TNX-801 is expected to enter a Phase 1 study in 2027 pending FDA clearance. TNX-801 is in the pre-IND stages of development.

Citations
1Schiller ZA, et al. J Clin Invest. 2021 131(11):e144843.
2Wang Y, et al. J Infect Dis. 2016. 214(2):205-11.
3Comstedt P, et al. Vaccine. 2015 33(44):5982-8.
4Connaught’s (ImuLyme™) and SmithKline Beecham’s (LYMErix™) Lyme disease vaccines were withdrawn. Nigrovic LE, et al. Epidemiol Infect. 2007 135(1):1-8. doi: 10.1017/S0950268806007096. Epub 2006 Aug 8. PMID: 16893489; PMCID: PMC2870557.
5Gomes-Solecki M, et. al. Clin Infect Dis. 2020 70(8):1768-1773. doi: 10.1093/cid/ciz872. PMID: 31620776; PMCID: PMC7155782.
6National Academies of Sciences, Engineering, and Medicine. 2025. Charting a Path Toward New Treatments for Lyme Infection-Associated Chronic Illnesses. Washington, DC: The National Academies Press. https://doi.org/10.17226/28578.

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals* is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg), is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. In addition, the Company’s CNS portfolio includes TNX-2900 (intranasal oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including long-acting human monoclonal antibody TNX-4800 for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X.

*Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially as a result of a number of factors, including the ability of the Company to satisfy the conditions to the closing of the offering and the timing thereof, as well as those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599

Brian Korb
astr partners
(917) 653-5122
brian.korb@astrpartners.com

Media Contacts
Deborah Elson
Tonix Pharmaceuticals 
deborah.elson@tonixpharma.com

Ray Jordan
Putnam Insights
ray@putnaminsights.com

Primary Logo

Source: Tonix Pharmaceuticals Holding Corp.

Released March 23, 2026

Release – Newsmax Appoints David Evans to Board of Directors

Posted on by aweinsoff@channelchek.com

Research News and Market Data on NMAX

March 23, 2026

Former CFO and COO Brings 25 Years of Public Company Financial and Operational Leadership

Evans Adds Digital Media Expertise to Newsmax Board as Company Expands Streaming Services
and Audience Reach

BOCA RATON, FL / ACCESS Newswire / March 23, 2026 / Newsmax Inc. (NYSE:NMAX) (“Newsmax” or the “Company”) today announced the appointment of David Evans to the Company’s Board of Directors, effective on Thursday, March 19th. Evans brings extensive public company financial leadership and digital media expertise to Newsmax as the Company continues to expand as one of America’s leading news networks.

“We are thrilled to welcome David Evans to the Newsmax Board of Directors,” said Christopher Ruddy, CEO of Newsmax. “David’s exceptional track record as a CFO and COO of a publicly traded multi-media company, combined with his deep expertise in both digital media transformation and the capital markets, makes him an invaluable addition to our Board. His professional background, specifically his deep experience scaling digital businesses, aligns perfectly with Newsmax’s strategic priorities as we continue to grow our streaming services and expand our overall reach.”

Evans joins the six existing members of the Newsmax Board of Directors including CEO Christopher Ruddy, U.S. Secretary of Labor Alex Acosta, Ambassador Nancy Brinker, Chris Nixon Cox, Ambassador Paula Dobriansky and David Gandler.

David Evans

David Evans is a board-ready executive and audit committee financial expert with 25 years of progressive leadership at a publicly listed multi-media company, including roles as Chief Financial Officer, Chief Operating Officer and Division President of New Media and Publishing. He combines deep expertise in financial oversight, SEC reporting and corporate governance with hands-on experience scaling digital media businesses across streaming, OTT TV, podcasting, e-commerce, digital advertising and social media.

Most recently serving as Chief Operating Officer of Salem Media Group from 2022 to 2025, Evans directed all operations with specific oversight of the digital media, e-commerce and finance functions. He previously served as Division President of New Media & Publishing from 2007 to 2021.

As Executive Vice President and Chief Financial Officer from 2000 to 2006, he instituted the company’s SOX compliance framework, helped triple the company’s stock price, executed a $93 million equity offering at a then record EBITDA multiple for the radio broadcast industry and secured more than $500 million in debt capital at industry-leading terms while guiding the company’s strategic pivot to digital media. Earlier, Evans held senior leadership positions at Warner Bros. Consumer Products, including Senior Vice President and Managing Director for Europe, Middle East and Africa.

Evans is a Chartered Accountants of England and Wales, where he achieved 5th place national ranking. He earned a Bachelor of Science (Honors) in Managerial and Administrative Studies with a specialization in Finance, Accounting and Strategic Planning from the University of Aston in Birmingham, England.

About Newsmax

Newsmax Inc. is listed on the NYSE (NMAX) and operates, through Newsmax Broadcasting LLC, one of the nation’s leading news outlets, the Newsmax channel. The fourth highest-rated network is carried on all major pay TV providers. Newsmax’s media properties reach more than 50 million Americans regularly through Newsmax TV, the N2 Channel, the Newsmax App, its popular website Newsmax.com, and publications such as Newsmax Magazine. Through its social media accounts, Newsmax reaches over 22 million combined followers. Reuters Institute says Newsmax is one of the top U.S. news brands and Forbes has called Newsmax “a news powerhouse.”

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning Newsmax’s strategic priorities, growth plans, streaming expansion, audience reach, digital initiatives, and the anticipated contributions of David Evans as a member of the Company’s Board of Directors. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause actual results to differ materially include, among others, changes in market, business, economic, competitive, technological, regulatory and other conditions, as well as the risks described from time to time in the Company’s periodic filings with the Securities and Exchange Commission. Newsmax undertakes no obligation to update any forward-looking statements, except as required by law.

For more information, please visit Investor Relations | Newsmax Inc.

Investor Contacts
Newsmax Investor Relations
ir@newsmax.com

SOURCE: Newsmax Inc.

View the original press release on ACCESS Newswire

Small Caps Surge 3% as Iran Talks Spark One of the Market’s Best Single-Day Reversals

Posted on by slightbourne@noblecapitalmarkets.com

The small-cap market opened Monday in the crosshairs of a global selloff, only to stage one of its most dramatic single-session recoveries in recent memory — all within the span of a few hours. The whipsaw move underscores just how vulnerable smaller, domestic-focused companies have become to the escalating conflict in the Middle East, and how quickly sentiment can shift on a presidential comment.

Going into this week, the Russell 2000 — the primary benchmark for small-cap equities — had already shed more than 7% in March alone, entering official correction territory last Friday with a decline exceeding 10% from its recent peak. The index, which had started the year as a market leader riding optimism around rate cuts and a rotation away from mega-cap tech, has now given back virtually all of those gains. As of last Thursday, the index’s year-to-date return had collapsed to less than 1%.

The catalyst for the unraveling has been the ongoing U.S.-Israel conflict with Iran. Since military operations began, Brent crude futures surged more than 40%, briefly touching $119 per barrel before pulling back. The ripple effects have been severe for small caps specifically. Unlike large-cap multinationals with diversified revenue streams and investment-grade credit, smaller companies are more exposed to rising input costs, tighter credit markets, and slowing consumer demand — the exact cocktail that an oil shock delivers.

The pain goes deeper than sentiment. Analysts now estimate that between 41% and 46% of Russell 2000 companies are unable to cover their interest expenses with operating income. These so-called zombie companies face a $368 billion debt maturity wall in 2026, and with the 10-year Treasury yield spiking to 4.38% by Friday — up sharply from the mid-3% range at the start of the year — refinancing that debt is significantly more expensive. The Federal Reserve’s decision to hold rates steady at 3.50%–3.75% at its March 18th meeting, while revising its inflation outlook upward, effectively removed any near-term cushion the market was counting on.

Then came Monday’s reversal.

Overnight, global markets were in freefall. South Korea’s KOSPI dropped over 6%, Japan’s Nikkei fell more than 3%, and European equities opened deep in the red. U.S. futures pointed to a fifth consecutive down week for American stocks. But within the first hour of trading, the picture changed completely. President Trump signaled he was postponing threatened strikes on Iranian power infrastructure, citing productive negotiations. Brent crude fell more than 10% on the news. U.S. equities surged, with the Russell 2000 climbing more than 3% intraday — one of the index’s strongest single-day moves of the year — reclaiming the 2,500 level.

For small-cap investors, this session captures exactly what makes the asset class both compelling and treacherous. Bank of America has noted that while the Russell 2000 tends to sell off more sharply than large caps in risk-off environments, it also tends to recover faster — historically outpacing large caps by more than a percentage point within three months of a geopolitical shock.

The Iran situation is far from resolved. But today’s action is a reminder that in small caps, the most dangerous moments often precede the most significant opportunities.

Release – SKYX Announces Corporate Update Call

Posted on by aweinsoff@channelchek.com

Research News and Market Data on SKYX

Company to Provide Corporate Updates including New Developments, Fourth Quarter 2025 and 2025 Full Year Overview and Financial Results; Conference Call to be Held on Thursday March 26, 2026, at 4:30 PM Eastern Time

March 23, 2026 09:00 ET  | Source: SKYX Platforms Corp.

MIAMI, March 23, 2026 (GLOBE NEWSWIRE) — SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the “Company” or “SKYX”), a highly disruptive smart home platform technology company with over 100 pending and issued patents globally and 60 lighting and home décor websites, with a mission to make homes and buildings become safe and smart as the new standard, announces today that it will host a Corporate Update call and present fourth quarter 2025 and 2025 full year overview and financial results. The conference call will be held on Thursday, March 26, 2026, at 4:30 p.m. Eastern Time.

SKYX Participating Members will Include:

  • Rani Kohen, Founder and Executive Chairman
  • Lenny Sokolow, CEO
  • Steve Schmidt, SKYX President, (Former CEO of Nielsen Data Corporation and former President of Office Depot International)
  • Marc Boisseau, CFO

SKYX Platforms – Q4 2025 and 2025 Full Year Corporate Update Call

Date: Thursday, March 26, 2026
Time: 4:30 p.m. Eastern Time
U.S./Canada Dial-in: 1-412-317-5180
International Dial-in: 1-844-825-9789 

Call me™ link for instant telephone access to the event: https://callme.viavid.com/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9JmluZm89Y29tcGFueSZyPXRydWUmYj0xNg==

Call me™ Passcode: 8524520

Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1757430&tp_key=97c42ef65d

Please dial in at least 10 minutes before the start of the call to ensure timely participation.
A playback of the call will be available until April 26, 2026. To listen, call within the United States and Canada or when calling internationally. Please use the replay pin number 10207623. A webcast is also available at the following link:
https://viavid.webcasts.com/starthere.jsp?ei=1757430&tp_key=97c42ef65d

About SKYX Platforms Corp.

As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced-safe-smart platform technologies, with over 100 U.S. and global patents and patent pending applications. Additionally, the Company owns 60 lighting and home decor websites for both retail and commercial segments. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at https://skyplug.com/ or follow us on LinkedIn.

Forward-Looking Statements

Certain statements made in this press release are not based on historical facts but are forward-looking statements. These statements can be identified by the use of forward-looking terminology such as “aim,” “anticipate,” “believe,” “can,” “could,” “continue,” “estimate,” “expect,” “evaluate,” “forecast,” “guidance,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “outlook,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “target” “view,” “will,” or “would,” or the negative thereof or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements reflect the Company’s reasonable judgment with respect to future events and are subject to risks, uncertainties and other factors, many of which have outcomes difficult to predict and may be outside our control, that could cause actual results or outcomes to differ materially from those in the forward-looking statements. Such risks and uncertainties include statements relating to the Company’s ability to successfully launch, commercialize, develop additional features and achieve market acceptance of its products and technologies and integrate its products and technologies with third-party platforms or technologies; the Company’s efforts and ability to drive the adoption of its products and technologies as a standard feature, including their use in homes, hotels, offices and cruise ships; the Company’s ability to capture market share; the Company’s estimates of its potential addressable market and demand for its products and technologies; the Company’s ability to raise additional capital to support its operations as needed, which may not be available on acceptable terms or at all; the Company’s ability to continue as a going concern; the Company’s ability to execute on any sales and licensing or other strategic opportunities; the possibility that any of the Company’s products will become National Electrical Code (NEC)-code or otherwise code mandatory in any jurisdiction, or that any of the Company’s current or future products or technologies will be adopted by any state, country, or municipality, within any specific timeframe or at all; risks arising from mergers, acquisitions, joint ventures and other collaborations; the Company’s ability to attract and retain key executives and qualified personnel; guidance provided by management, which may differ from the Company’s actual operating results; the potential impact of unstable market and economic conditions on the Company’s business, financial condition, and stock price; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including its periodic reports on Form 10-K and Form 10-Q. There can be no assurance as to any of the foregoing matters. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by U.S. federal securities laws.

Investor Relations Contact:

Jeff Ramson
PCG Advisory
jramson@pcgadvisory.com

Release – Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

Posted on by aweinsoff@channelchek.com

Research News and Market Data on OCGN

March 23, 2026

PDF Version

MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with key opinion leaders (KOLs) and Ocugen executive leadership to discuss the full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy (GA), late-stage dry age-related macular degeneration (dAMD) at 8 a.m. EDT on Tuesday, March 24, 2026.

KOLs leading the webcast include:

  • Lejla Vajzovic, MD, FASRS, Professor of Ophthalmology, Director of CME-Ophthalmology, Duke University School of Medicine & Chairman, Ocugen Scientific Advisory Board
  • Jay Chhablani, MD, Professor, University of Pittsburgh and UPMC Vision Institute, and President of NetraMind

Victor H. Gonzalez, MD, Retinal Surgeon, Valley Retina Institute, McAllen, Texas, Faculty at University of Texas Rio Grande Valley; and Syed M. Shah, MD, Vice Chair for Research and Digital Medicine, Director of Retina Service, Department of Ophthalmology at Emplfiy Health, La Crosse, WI, Ibn al-Haytham Professor, Department of Ophthalmology, Aga Khan University will join to answer questions.

Attendees are invited to participate on the call using the following details:

Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 4629682
Webcast: Available on the events section of the Ocugen investor site

A replay of the call and archived webcast will be available following the event on the Ocugen investor site.

About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com